Ellacor Micro-Coring: FDA-Cleared Skin Removal Without Surgery or Heat

For decades, the field of non-surgical skin tightening has been dominated by thermal energy. Whether using lasers, radiofrequency, or microfocused ultrasound, these devices all work by heating the skin to trigger a controlled thermal injury, which contracts collagen and stimulates tissue repair.

The Ellacor System (developed by Cytrellis Biosystems, Inc.) represents a departure from this thermal paradigm. Rather than using heat to shrink tissue, Ellacor physically removes full-thickness columns of skin using hollow, high-speed micro-needles. This process—known as micro-coring—is designed to tighten the skin envelope mechanically, offering a non-surgical alternative for tissue removal.

This dossier provides an evidence-first analysis of the Ellacor System, evaluating its mechanical action, FDA clearance timeline (including the October 2025 body-resurfacing expansion), post-market safety record (including the two 2023 recalls and MAUDE database counts), and clinical limitations, specifically its exclusion of darker skin types.

---

1. What Is Ellacor Micro-Coring — and How Is It Different From Microneedling, RF Microneedling, and Laser?

To evaluate Ellacor, one must understand its position in the landscape of dermatological rejuvenation. It is not a variation of microneedling or fractional laser; it is a distinct mechanical modality.

Modality Differences in Skin Tightening:
┌────────────────────────┬────────────────────────────────────────────────────────┐
│ Modality               │ Tissue Action                                          │
├────────────────────────┼────────────────────────────────────────────────────────┤
│ Standard Microneedling │ Punctures skin with solid needles (no tissue removal)  │
│ RF Microneedling       │ Punctures skin + delivers thermal energy (heat injury) │
│ Fractional CO2 Laser   │ Thermally vaporizes columns of tissue (thermal ablation)│
│ Ellacor Micro-Coring   │ Mechanically cores & removes skin columns (no heat)     │
└────────────────────────┴────────────────────────────────────────────────────────┘

The Mechanical Tissue-Removal Mechanism

The Ellacor system uses a handpiece containing a rapid-firing array of hollow-core needles (typically 22-gauge, with an internal diameter of approximately 0.5 mm). When activated, the handpiece drives these needles into the skin at high speed, core-drills a cylindrical column of tissue spanning the epidermis and dermis, and extracts the core via a continuous vacuum system.

By removing these micro-cores, Ellacor removes up to 7% to 8% of the skin surface area in a single treatment zone. Because each micro-core is less than 0.5 mm in diameter, the puncture sites are below the biological threshold that triggers visible scar tissue formation (which typically occurs at punctures larger than 0.5 mm).

Instead of scarring, the surrounding tissue collapses and contracts to close the microscopic voids. The skin heals via primary intention, resulting in a reduction in overall skin surface area and a mechanical tightening effect without the use of heat.

Comparison to Thermal and Puncture-Only Modalities

Clinicians and patients often confuse micro-coring with adjacent modalities:

1. Standard Microneedling: Uses solid needles to puncture the skin, creating temporary channels to trigger a healing response. Microneedling does not remove any skin tissue; it simply displaces it. For a detailed breakdown of this mechanism, see our guide on microneedling vs RF microneedling — what each actually does.
2. Radiofrequency (RF) Microneedling (e.g., Morpheus8): Combines solid needle punctures with radiofrequency energy delivered at the needle tips. This heats the deep dermis and subdermal fat to promote contraction. RF microneedling is highly effective, but it carries a risk of post-inflammatory hyperpigmentation (PIH) and fat necrosis. For comparative cost structures, see our dossier on Morpheus8 cost and what it treats.
3. Fractional CO2 Laser: Uses light energy to thermally ablate (vaporize) columns of skin. While effective at removing tissue, it generates a significant zone of thermal damage (coagulation zone) around each ablated column. This thermal zone requires a longer downtime and carries risks of persistent redness, scarring, and pigmentary changes. For laser risk profiles, see our guide on CO2 laser resurfacing complications and recovery.

---

2. Engineering and Device Architecture: How the Micro-Coring Handpiece Functions

Understanding the mechanical engineering behind the Ellacor System is essential to differentiate it from standard electromechanical aesthetic devices. The system comprises a console, a foot pedal, and a specialized single-use handpiece cartridge.

Ellacor Mechanical System Architecture:
┌────────────────────────┐
│     Console & Pump     │ ── (Calibrated Vacuum Pressure)
└───────────┬────────────┘
            │ (Umbilical Cable: Power / Fluidics / Vacuum)
┌───────────▼────────────┐
│   Actuator Handpiece   │ ── (Up to 1,000 needle cycles/min)
└───────────┬────────────┘
┌───────────▼────────────┐
│ Disposable Cartridge   │ ── (Hollow 22-Gauge Needles with 0.5mm ID)
└────────────────────────┘

Needle Configuration and Actuation Speed

The disposable cartridge contains an array of hollow-core needles (ranging from 10 to 20 needles per cartridge block). Unlike microneedling pens that actuate in a simple reciprocating vertical motion, the Ellacor handpiece utilizes a highly synchronized motor drive that combines vertical actuation with high-velocity rotation to cleanly slice through the dermal layer.

The actuation frequency reaches up to 1,000 cycles per minute. This high speed is critical to minimize lateral shearing forces, which would otherwise tear the dermis and lead to scarring.

The Fluidic and Vacuum Aspiration System

To ensure complete tissue extraction, the console houses a high-pressure vacuum pump. The hollow needles are connected via a manifold to a vacuum channel in the handpiece.

As the needles pierce the skin and reach their targeted depth, the vacuum activates, aspirating the cut cylinder of skin through the needle bore and depositing it into a sterile waste collection jar in the console.

If the vacuum pressure is insufficient, the micro-cores remain in the tissue (becoming retained plugs), which leads to localized infection, foreign-body reactions, and failure to contract.

---

3. What Is Ellacor FDA-Cleared For — Face (2021) and Body (2025) Indications Explained

The regulatory clearance of the Ellacor system spans two distinct 510(k) clearances under FDA product code QAI (powered microneedle device).

The Original 2021 Facial Clearance (K202517)

On July 9, 2021, the FDA cleared the Cytrellis Dermal Micro-Coring System under 510(k) Number K202517 (Cytrellis announced the clearance publicly on July 27, 2021). The cleared indication was:

"Indicated for use by medical professionals for the treatment of moderate and severe wrinkles in the mid and lower face in adults aged 22 years or older with Fitzpatrick skin types I to IV."

The clearance was supported by a pivotal clinical trial (NCT 03573271) involving 51 subjects who received 2 to 3 treatments, removing approximately 7% to 8% of skin area per treatment at depths up to 5 mm.

The trial demonstrated significant improvement in mid-to-lower face wrinkles, with a high safety profile. However, the clearance was restricted to Fitzpatrick skin types I to IV, which represents a critical safety limitation for patients with darker skin tones.

Detailed Pivotal Trial Metrics (NCT 03573271)

The peer-reviewed analysis of the pivotal trial (published in Lasers in Surgery and Medicine) reports several clinically meaningful parameters:

• Wrinkle Severity Reduction: The mean improvement on the Lemperle Wrinkle Severity Scale was 1.3 grades at the 90-day assessment, and an independent reviewer panel correctly identified 84.2% (245 of 291) of post-treatment photographs as improved.
• Global Aesthetic Improvement: Evaluators recorded improvement on the Global Aesthetic Improvement Scale (GAIS) for 89.7% (87 of 97) of treated sides.
• Patient Satisfaction: Participants reported satisfaction with 85.6% of treatment sites.
• Recovery: Procedure-related bleeding and pain were mild, with a patient-reported average downtime of about 3 days — consistent with the local-anesthetic, non-thermal protocol.

Cytrellis states that the full subject-level pain (Wong-Baker 0–10 scale), GAIS, and satisfaction datasets are on file with the company and were submitted to the FDA as part of the 510(k); the figures above are drawn from the published peer-reviewed analysis.

The October 2025 Body Expansion (K252752)

On October 30, 2025, Cytrellis received a secondary clearance under 510(k) Number K252752 for the ellacor System with Micro-Coring Technology. This clearance expanded the system's indications to include:

"Fractional skin resurfacing to treat wrinkles and laxity on the body, specifically the abdomen, upper arms, and knees."

This clearance represents a significant market expansion, positioning Ellacor as a non-surgical option for body skin laxity, particularly for patients experiencing skin excess after pregnancy or moderate weight loss.

---

4. Cost, Downtime, and How Many Treatments You Actually Need

While micro-coring is non-surgical, it requires local anesthesia and involves a healing process that distinguishes it from standard "lunchtime" med-spa treatments.

The Treatment Protocol and Anesthesia

Because the hollow needles penetrate up to 5 mm deep into the dermis (where nerve endings are dense), the procedure cannot be performed with topical numbing creams alone.

It requires a local anesthetic infiltration (typically lidocaine with epinephrine) injected across the treatment area. The procedure takes 30 to 45 minutes for a full mid-to-lower face treatment.

Typical Treatment Course

Unlike a facelift, which is a single surgical event, optimal micro-coring results are cumulative. The standard protocol requires 2 to 3 treatment sessions spaced 4 to 6 weeks apart.

This spaced delivery allows the skin to heal and contract incrementally without overwhelming the tissue's regenerative capacity.

Downtime Expectations

Downtime is mechanical, consisting of bleeding, swelling, bruising, and a sandpaper-like texture as the micro-crusts heal.

• Days 1 to 3: Moderate swelling, redness, and pinpoint bleeding. The skin must be kept clean and covered with an occlusive ointment.
• Days 4 to 7: Redness transitions to a pink hue, and swelling subsides. Micro-crusts begin to shed. Most patients can return to work and apply makeup by day 5 to 7.

This recovery timeline is significantly shorter than that of deep chemical peels or ablative fractional CO2 lasers, which require 10 to 14 days of recovery and carry a prolonged risk of persistent redness.

True Cost Math

The cost of Ellacor is clinic-dependent and varies by region. The average cost ranges from $1,500 to $2,500 per session. A complete three-session treatment course costs $4,500 to $7,500.

When compared to a surgical facelift (which runs $15,000 to $35,000 all-in), Ellacor represents a lower initial cost, though it remains a premium device treatment.

---

5. Who Is NOT a Candidate — the Fitzpatrick I-to-IV Limitation and Skin-of-Color Risk

The most significant clinical limitation of the Ellacor system is its strict candidacy gate: it is cleared only for patients with Fitzpatrick skin types I to IV.

The Exclusion of Fitzpatrick Types V and VI

Fitzpatrick skin types V and VI represent darker skin tones (such as deeply pigment-rich brown and black skin). The FDA clearance specifically excludes these groups due to the biological response of melanocytes (the pigment-producing cells in the skin) to mechanical trauma.

When hollow needles perform full-thickness tissue removal in pigment-rich skin, the mechanical trauma and subsequent healing response trigger a high rate of post-inflammatory hyperpigmentation (PIH) or permanent hypopigmentation (loss of pigment, leaving white micro-spots where the cores were removed).

Furthermore, patients with Fitzpatrick types V and VI have a higher genetic predisposition to keloid or hypertrophic scar formation. If the micro-punctures trigger a keloid response, the patient can develop thousands of tiny, raised scars across the treatment area.

Safety Guidance

Practitioners must perform a formal skin typing assessment prior to recommending Ellacor. For patients of color with Fitzpatrick V or VI skin who seek lower-face tightening, alternative treatments must be utilized.

These include energy devices with safety profiles validated for darker skin, such as Nd:YAG lasers or microfocused ultrasound with conservative parameters. For a detailed analysis of these protocols, see our guide on energy-device safety for skin of color.

---

6. Provider Training, Scope of Practice, and Clinical Credentials

Because the Ellacor System performs mechanical skin excision (removal of tissue) rather than simple dermal injury, it occupies a unique regulatory position in state-level scopes of practice. It is critical for clinical operators and med spa directors to understand who can legally operate this device.

The "Practice of Medicine" Classification

Unlike standard microneedling (which is often regulated under esthetician licenses depending on needle depth), micro-coring is universally classified as a medical procedure. There are two primary regulatory triggers:

1. Dermal Excision: The device physically removes full-thickness columns of tissue. State medical boards generally define the surgical excision of tissue as the practice of medicine.
2. Prescription Anesthetic Requirement: Because the hollow needles actuate at high speed to a depth of 5 mm, the procedure cannot be tolerated under topical anesthetics alone. It requires local anesthetic infiltration (typically 1% to 2% lidocaine with epinephrine). In all U.S. jurisdictions, lidocaine is a prescription legend drug that must be prescribed and administered by a licensed medical provider.

Permitted Operators by State Rule

Due to these triggers, the operation of the Ellacor System is restricted:

• Physicians (MD/DO): Can perform the procedure without restriction and act as the supervising medical director.
• Mid-Level Providers (PA/NP): Can perform the procedure under standard collaborative or supervisory agreements with a physician.
• Registered Nurses (RN): In many states, an RN can operate the device only after a physician has performed a face-to-face "good faith examination" of the patient, diagnosed the condition, prescribed the procedure, and formally delegated the administration of the local anesthetic and device operation under direct supervision.
• Aestheticians: Aestheticians and laser technicians are strictly prohibited from operating the Ellacor System or injecting local anesthetics in all U.S. states. Utilizing non-licensed staff to perform micro-coring represents the unlicensed practice of medicine and exposes the practice to severe board disciplinary action and malpractice liability.

---

7. Is Ellacor Safe — the FDA MAUDE Reports and the Two 2023 Recalls

To evaluate Ellacor's safety profile, we must examine the FDA's post-market surveillance data, including Manufacturer and User Facility Device Experience (MAUDE) reports and product recalls.

MAUDE Database Adverse Event Breakdown

Under FDA product code QAI (powered microneedle device), the MAUDE database contains 28 reports specifically associated with Cytrellis and Ellacor-branded systems:

• ELLACOR SYSTEM WITH MICRO-CORING TECHNOLOGY: 24 reports.
• CYTRELLIS MICRO-CORING SYSTEM: 1 report.
• ELLACOR: 3 reports.

The reported adverse events predominantly consist of:

1. Persistent Erythema (Redness): Redness persisting beyond 30 days post-procedure.
2. Post-Inflammatory Hyperpigmentation (PIH): Darkening of the skin at the treatment site, often resolving with topical therapy over 3 to 6 months.
3. Micro-Scarring or Textural Irregularities: Small pinpoint depressions or a cobblestone texture in cases where treatments were performed at high density or in patients with poor healing capacity.
4. Infection: Localized bacterial infections requiring oral antibiotics.

Compared to the millions of procedures performed in the injectables category, 28 MAUDE reports represent a limited and manageable safety footprint, indicating that when performed by trained operators on appropriate candidates, the device displays a high safety margin.

The Two 2023 Recalls

In 2023, the FDA registered two recalls for the Cytrellis Dermal Micro-Coring System:

1. Recall Number Z-1648-2023 (April 7, 2023):
   • Status: Completed.
   • Reason: Use error. The recall was initiated to update the user manual and clinical training protocols to address user errors that led to needle bending or misalignment when the handpiece was applied at incorrect angles.
2. Recall Number Z-2393-2023 (June 23, 2023):
   • Status: Open / Classified.
   • Reason: Process control. Cytrellis initiated a voluntary recall to address a manufacturing process control issue where a subset of needle assemblies did not meet internal tensile strength specifications, potentially leading to needle structural failure during high-speed actuation.

These recalls show the developmental iterations of this mechanical technology. Clinical operators must ensure their systems are updated and that they follow the revised handpiece application protocols to prevent use-related complications.

---

8. Ellacor vs. a Facelift — When Skin Removal Helps and When Surgery Still Wins

Because Ellacor physically removes skin, it is marketed as a "non-surgical skin removal" option. However, clinical operators must position the device appropriately against the surgical ceiling.

Volume Limits of Skin Removal

In a three-treatment course, Ellacor can remove up to approximately 15% to 22% of the skin envelope in a targeted area (assuming a 7% removal rate per session). This is a substantial reduction for a non-surgical device and is highly effective for softening moderate wrinkles and early laxity.

However, a surgical facelift does not just remove skin; it lifts and suspends the deep SMAS layer, shifts fat compartments, and removes several inches of excess skin. For patients with prominent jowling, severe neck laxity, or significant skin excess, Ellacor cannot match the structural repositioning of a facelift.

Cost and Longevity Comparison

The following table contrasts the parameters of Ellacor with those of a surgical facelift:

For patients with moderate lower-face aging who are not candidates for surgery due to medical contraindications or personal preference, Ellacor represents an evidence-based alternative. However, if a patient has advanced laxity, investing in a multi-session Ellacor course may under-deliver, making a surgical facelift more cost-effective. For surgical options, see our guide on facelift cost, recovery, and types.

---

FAQ

Is ellacor just a fancy microneedling device, or does it actually do something different?

Ellacor is fundamentally different from microneedling. Standard microneedling uses solid needles to puncture the skin, creating temporary channels to stimulate collagen without removing any tissue. Ellacor uses hollow-core needles that act as micro-punches, physically removing cylinders of skin tissue and extracting them via vacuum. This results in a physical reduction of skin surface area (mechanical tightening), whereas microneedling only stimulates healing within the existing skin volume.

Can I get ellacor if I have darker skin (Fitzpatrick V to VI)?

No, the Ellacor system is currently FDA-cleared and clinically indicated only for patients with Fitzpatrick skin types I to IV. Darker skin tones (types V and VI) carry a high risk of post-inflammatory hyperpigmentation (PIH), permanent hypopigmentation (white spots), and keloid scar formation in response to the mechanical trauma of micro-coring. If you have darker skin, you should seek alternative tightening modalities that are validated as safe for skin of color.

How much does ellacor cost and how long do results last compared to a facelift?

A complete three-session Ellacor course typically costs $4,500 to $7,500, with results persisting for approximately 18 to 24 months before natural aging and skin laxity necessitate maintenance sessions. A surgical facelift costs $15,000 to $35,000 all-in, but provides structural lifting of the SMAS layer and skin removal that lasts 7 to 10+ years.

Has ellacor had any FDA recalls or safety problems I should know about?

Yes, Cytrellis initiated two voluntary FDA recalls in 2023: one in April (Z-1648-2023, Completed) to update clinical user manuals and address use errors that caused needle bending, and one in June (Z-2393-2023, Open/Classified) to address a manufacturing defect in a subset of needle assemblies. Additionally, there are approximately 28 adverse event reports in the FDA MAUDE database for Ellacor-branded devices, primarily involving persistent redness, localized skin infections, and minor textural irregularities.

---

Sources

• Food and Drug Administration (FDA): 510(k) Clearance for ellacor System with Micro-Coring Technology. 510(k) Number: K252752. Sourced from: https://www.accessdata.fda.gov/cdrh_docs/pdf25/K252752.pdf
• Food and Drug Administration (FDA): 510(k) Clearance for Cytrellis Dermal Micro-Coring System. 510(k) Number: K202517. Sourced from: https://www.accessdata.fda.gov/cdrh_docs/pdf20/K202517.pdf
• Food and Drug Administration (FDA): FDA Recalls Database (Product Code QAI, Recalls Z-1648-2023, Z-2393-2023). Sourced from: https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfres/res.cfm
• Cytrellis Biosystems: Clinical Results and Pivotal Trial Parameters (NCT 03573271). Sourced from: https://www.cytrellis.com/technology/clinical-results
• Peer-reviewed pivotal trial analysis (Lasers in Surgery and Medicine): Dermal Micro-coring for the Treatment of Moderate to Severe Facial Wrinkles — Lemperle, GAIS, satisfaction, and downtime outcomes. PMC9575956. Sourced from: https://pmc.ncbi.nlm.nih.gov/articles/PMC9575956
• Plastic Surgery Practice: Ellacor and the Rise of Micro-Coring: Insights from the Clinic and the Company (July 2025). Sourced from: https://plasticsurgerypractice.com/treatment-solutions/innovations/ellacor-and-the-rise-of-micro-coring-insights-from-the-clinic-and-the-company
• The Dermatology Digest (Nov 2025): U.S. FDA Clears Ellacor Micro-Coring Technology for Full-Body Resurfacing. Sourced from: https://thedermdigest.com/u-s-fda-clears-ellacor-micro-coring-technology-for-full-body-resurfacing